Факторы прогноза и эффективность лечения больных с рецидивами несеминомных герминогенных опухолей у мужчин
Диссертация
Применение другой классификации течения рецидивов ГО, предложенной Beyer J. с соавторами, оказалось высоко эффективным на нашей популяции больных с рецидивами НТО. Используя данную классификацию, удается выделить больных, которые отличаются благоприятным течением рецидива и реагируют на «любую» XT второй линии (все 36 больных из группы благоприятного прогноза живы, с медианой наблюдения 22… Читать ещё >
Список литературы
- Тюляндин С.А., Трякин А. А., Буланов А. А. с соавторами. Опыт Российского онкологического центра в лечении пациентов с распространенными герминогенными опухолями // Онкоурология. 2005. № 3. С. 60−65.
- Давыдов М.И., Аксель Е. М. «Статистика злокачественных новообразований в России и странах СНГ в 2006 г.» // Вестник онкологического научного центра им. Н. Н. Блохина РАМН. 2008. т. 19. № 2, приложение 1.
- Матвеев Б.П., Волкова М. И. Герминогенные опухоли яичка. Эпидемиология. Этиология. Классификация. Клиника и диагностика // Андрология и генитальная хирургия. 2001. № 3. С. 35−42.
- Трякин А.А., Буланов А. А., Тюляндин С. А. Индукционная химиотерапия метастатических герминогенных опухолей // Практическая онкология. 2006. 7(1). С.30−38.
- Тюляндин С.А. Лечение диссеминированных герминогенных опухолей у мужчин // Материалы VI Росс, онкол. конф. 26−28 ноября 2002 г. М., 2002.
- Титов Д.А. Химиотерапия больных несеминомными герминогенными опухолями яичка с плохим прогнозом/ Дисс. на соискание степени к. м. н. М. 1999.
- Bhatia S., et al. High-Dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer//J. Clin. Oncol. 2000. 18:3346−3351.
- Проценко С.А. Лечение рецидивов герминогенных опухолей // Практическая онкология. Том 76 № 1 -2006.
- Фигурин К.М. Тактические подходы к лечению рецидивов герминогенных опухолей яичка. Материалы VI Всероссийского, съезда онкологов. 11 — 14 октября 2006 г. Р-Д.
- Broun E.R., Nichols C.R., Kneebone P., et al. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherару and autologous bone marrow rescue // Ann. Intern. Med. 1992 Jul 15−117(2):124−8
- Kondagunta G., Bacik J., Sheinfeld J., et al. Paclitaxel plus ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors // J. Clin. Oncol. 25:85−90. 2007
- Margolin K., Doroshow J.H., Ahn C., Hamasaki V. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support // J. Clin. Oncol. 1996 Oct-14(10):2625−6.
- Motzer R.J., Geller N. L., Tan C.Y. Salvage chemotherapy for patients with germ cell tumors. Cancer// 1991. 67:1305−1310.
- Donadio A., Sheinfeld J., Bacik J., et al. Treatment for patients (pts) with relapsed testicular germ cell tumors (GCT). Proc Am. Soc. Clin. Oncol. 2003, 1537 (abstr.).
- Droz J.P., Kramar A., Nichols C.R., et al. Second line chemotherapy with ifosfamide, cisplatin and either etoposide or vinblastine in recurrent germ cell cancer: Assignment of prognostic groups. Proc. Am. Soc. Clin. Oncol. 12:229, 1993 (abstr 704).
- Fossa S.D., Stenning S.P., Horwich A., et al. Prognostic factors for survival in patients with malignant germ cell tumors (GCT) relapsing after cisplatin-based chemotherapy. Proc. Am. Soc. Clin. Oncol. 16: 333a, 1997 (abstr).
- Tryakin A., Tjulandin S., Titov D., et al. C-BOP-3BEP as induction chemotherapy (CT) in nonseminomatous germ cell tumor (NSGCT) patients with poor prognosis // J. Clin. Oncol., ASCO Annual Meeting Proceedings, 22 (14S), 2004: 4748.
- Hartmann J.T., Einhorn L., Nichols C.R., et al. Second-line chemotherapy in pa. tients with relapsed extragonadal nonseminomatous germ cell tumors: results ofan international multicenter analysis. J. Clin. Oncol., 2001- 19, (6): 1641−1648.
- Loehrer P.J., Gonin R., Nichols C.R., et al. Vinblastine plus ifosfamide plus cis-platin as initial salvage therapy in recurrent germ cell tumor // J. Clin. Oncol., 1998, 16, pp 2500−2504.
- Gerl A., Clemm C., Schmeller N., et al. Prognosis after salvage treatment for unselected male patients with germ cell tumors // Br. J. Cancer. 1995. 72: 10 261 032,
- Beyer J., Kramar A., Mandanas R., et al. High-dose chemotherapy as salvage treatment in germ cell tumors. A multivariate analysis of prognostic variables // J. Clin. Oncol. 1996- 14:2638−45.
- Vaena D.A., Abonour R., Einhorn L.H. Long-term survival after high-dose salvage chemotherapy for germ cell malignancies with adverse prognostic variables. Proc. Am. Soc. Clin. Oncol. 2003- 1538 (abstr).
- Porcu P., Bhatia S., Sharma M., Einhorn L. H: Results of treatment after relapse from high-dose chemotherapy in germ cell tumors // J. Clin. Onco. 2000- 18(6): 1181−1186.
- Greco F.A., Johnson D.H., Hainsworth J.D. Chronic oral etoposide // Cancer. t1991.67:303−309.
- Loehrer P.J. Etoposide therapy for testicular cancer // Cancer. 1991. 67 220−224.
- Harstrick A., Schmoll H.J., Wilke H., et al. Cisplatin, etoposide, and ifosfamide salvage therapy or refractory or relapsing germ cell carcinoma // J. Clin. Oncol. 9:1549−1555. 1991.
- Pizzocaro G., Salvioni R., Piva L., et al. Modified cisplatin, etoposide (or vinblastine) and ifosfamide salvage therapy for male germ-cell tumors. Long-term results // Annals of Oncology. 1992. 3:211−216.
- McCaffrey J.A., Mazumdar M., Bajorin D.F., et al. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival //J. Clin. Oncol. 1997. 15:2559−2563.
- Shamash J., Oliver R.T., Ong J., et al. Sixty percent salvage rate for germ-cell tumours using sequential m-BOP, surgery and ifosfamide-based chemotherapy // Ann. Oncol. 1999, 10, (6) — pp 685−692.
- Bedano P.M., Brames M.J., Williams S.D., et al. Phase II study of cisplatin plus epirubicin salvage chemotherapy in refractory germ cell tumors // J. Clin. Oncol. 2006. 24:5403−5407.
- Madani A. A., George D. W., Brames J. M., Einhorn L. E. Phase II study of epirubicin pluse cisplatin in refractory germ cell tumors. Proc. Am. Soc. Clin. Oncol. 2003,1557 (abstr.).
- Motzer R.J., Chou T.C., Schwartz L., et al. Paclitaxel in germ cell cancer // Semin. Oncol. 1995−22:12−5.S.
- Bokemeyer C., Beyer J., Metzner В., et al. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer // Ann. Oncol. 1996. 7,(1): 31−34.
- Sandler A.B., Cristou A. et al. A phase II trial of paclitaxel in refractory germ cell tumors // Cancer. 1998- 82:1381−6.
- Motzer R.J., Sheinfeld J., Mazumdar M., et al. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer // J. Clin. Oncol. 2000. 18, (12): 2413−2418.
- Donadio A., Sheinfeld J., Bacik J., et al. Paclitaxel, ifosfamide and cisplatine (TIP): an effective second-line therapy for patients (pts) wiyh relapsed testicular germ cell tumors (GCT). Proc. Am. Soc. Clin. Oncol. 2003, 1537 (abstr.).
- Berrutil A., Sainil A., Gorzegnol G., et al. Durable complete remission after weekly docetaxel administration in a patient with mediastinal nonseminomatous germ-cell tumor refractory to cisplatin-based chemotherapy // Ann. Oncol. 1993. 10: 420−424.
- Amato R. J.', Prow D. M., et al. Paclitaxel-based chemotherapy for patients with refractory or relapsed nonseminomatous germ cell tumors // Urologic Oncology. 5 (2000) 134−138.
- Bokemeyer C., Gerl A., Schoffski P., et al. Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J. Clin. Oncol., 1999, 17, (2):512.
- Einhorn L.H., Michael J., Stender M.J., Williams S.D. Phase II trial of gemcitabine in refractory germ cell tumors // J. Clin. Oncol. 1999. 17, (2): 509.
- Hinton S., Catalano P., Einhorn L.H., et al. Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group //J. Clin. Oncol. 2002. 1- 20(7): 1859−63.
- Pizzocaro G., Nicolai N., Salvioni R., et al. Paclitaxel, cisplatin, gemcitabine (TGP) third line therapy in metastatic germ cell tumors (GST) of the testis. Proc. Am. Soc. Clin. Oncol. 2001, 773 (abstr).
- Dunn T.A., Schmoll H.J., Grunwald V., et al. Comparative cytotoxicity of ox-aliplatin and cisplatin in non-seminomatous germ cell cancer cell lines. Invest. New Drugs. 1997−15(2):109−14.
- Kollmannsberger C., Rick O., Derigs H.-G., et al. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group // J. Clin. Oncol. 2002. 20 (8): 2031−2037.
- Soulie P, Garrino C, Bensmaine MA, et al. Antitumoral activity of ox-aliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell1 cancer patients//J. Cancer Res. Clin. Oncol. 1999 Dec- 125(12):707−11.
- Bokemeyer C., Beyer J., Metzner В., et al. Combination chemotherapy with gemcitabine/oxaliplatin in relapsed or cisplatin-refractory germ cell cancer (GCT). Proc. Am. Soc. Clin. Oncol. 2003, 1561 (abstr.).
- Pectasides M., Farmakis D., et al. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study D // Ann. of Oncol. 2004. 15: 493−497.
- Giorgia U.D., Rosti G., Aieta M, et al. Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminoma-tous germ cell tumor // European urology, 50 (2006) 1032−1039.
- De Giorgi U., Rosti. G., Papiani G., et al. Weekly gemcitabine, paclitaxel, oxaliplatin combination chemotherapy in patients with cisplatin-refractory germ cell tumor: preliminary experience // Am. J. Clin.Oncol. 2004. 27: 457−60.
- Kollmannsberger C., Rick O., Klaproth H., et al. Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II' study of the German Testicular Cancer Study Group //Br. J. Cancer. 2002. 23−87(7):729−32.
- Miki Т., Mizutani Y., Nonomura N., et al. Irinotecan plus cisplatin has substantial’antitumor effect as salvage chemotherapy against germ cell tumors // Cancer. November 1, 2002. Volume 95. № 9.
- Raymond E., Faivre S., Woynarowski J.M., et al. Oxaliplatin: mechanism of action and antineoplastic activity // Semin. Oncol. 1998- 25:4−12.
- Wasserman E., Cuvier C., Lokiec F., et al. Combination of oxaliplatin plus iri-notecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics // J. Clin. Oncol. 1999. 17:1751−9.
- Lampe H., Dearnaley D.P., Price A., et al. High-dose carboplatin and etoposide for (salvage chemotherapy of germ cell tumors // Eur. J. Cancer., 1995. 31A (5):717−23.
- Linkesch W., Greinix H.T., Hicker P., et al. Long-term follow up of phase I/II trial of ultrahigh carboplatin, VP 16, cyclophosphamide with ABMT in refractory or relapsed NSGCT. Proc. Am. Soc. Clin. Oncol. 1993. 12:232, (abstr 717).
- Rick O., Beyer J., Kingreen D., et al. High-dose chemotherapy in germ cell tumors: a large single centre experience // Eur. J. Cancer. 1998. 34(12):1883−8.
- Rodenhuis S., Wit R., Mulder P.H., et al. A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission//Ann. Oncol. 1999. 10 (12):1467−1473.
- Motzer R.J., Mazumdar M., Sheinfeld J., et al. Sequential dose-intensive pacli-taxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients//J. Clin. Oncol. 2000. 18,(6): 1173−1180.
- Bhatia S., et al., High-Dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer // J. Clin. Oncol. 2000. 18:3346−3351.
- De Giorgi U., Demirer Т., Wandt H., et al. Second-line high-dose chemotherapy in patients with mediastinal and retroperitoneal primary non-seminomatous germ cell tumors: the EBMT experience //Ann. Oncol. 2005. 16: 146−151.
- McNeish I-.A., Kanfer E.J., Haynes R., et al. Paclitaxel-containing high-dose chemotherapy for relapsed or refractory testicular germ cell tumors // British Journal of Cancer. 2004. 90, 1169 1175.
- Rosti G., Pico J.-L., Wandt H., et al. High-dose chemotherapy (HDC) in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumors (GCT) — first results, of a prospective randomized trail of the
- European group for blood and marrow transplantation (EBMT): IT-94 study. Proc. Am. Soc. Clin. Oncol., 2002: Abstr. 716.
- Kondagunta G.V., Bacik J., Sheinfeld J. Paclitaxel plus ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors // J. Clin. Oncol. 2007. 25:85−90.
- Vaena D.A., Abonour R., Einhorn L. H. Long-term survival after high-dose salvage chemotherapy for germ celb malignancies with adverse prognostic variables//J. Clin. Oncol. 2003. 21:4100−4104.
- McGlynn K.A., Devesa S.S., Graubard B.I., et al. Increasing incidence of testicular germ cell tumors among black men in the United States // J. Clin. Oncol. 2005.23:5757−61.
- Ronnen E.A., Kondagunta G.V., Bacik J., et al. Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy // J. Clin. Oncol. 2005- 23: 6999−7004.
- Shahidi M., Norman A.R., Dearnaley D.P., et al. Late recurrence in 1263 men with testicular germ cell tumors, multivariate analysis of risk factors and implications for management// Cancer. 2002- 95:520−30.
- Oldenburg J., Alfsen G.C., Waehre H., Fossa S.D. Late recurrences of germ cell malignancies: a population-based experience over three decades // British Journal of Cancer. 2006. 94, 820 827.
- George D.W., Foster R.S., Hromas R.A., et al. Update on late relapse of germ cell tumor: a clinical and molecular analysis // J. Clin. Oncol. 2003. 21:113−122.
- Geldart T.R., Gale J., McKendrick J. et al. Late relapse of metastatic testicular nonseminomatous germ cell cancer: surgery is needed for cure // British J. urology Int. 2006 Aug. 98(2):353−8.
- Sharp D.S., Carver B.S., Eggener S.E., et al: Clinical outcome of patients managed for late relapse of germ cell tumor // J. Clin. Oncol. 2006. 24:229s (suppl- abstr 4550).
- Carver B.S., Motzer R. J., Kondagunta G.V., et al. Late relapse of testicular germ cell tumors // Urologic Oncology: Seminars and Original Investigations. 2005.23, 441−446.
- Gerl A., Clemm C., Schmeller N., et al. Late relapse of germ cell tumors after cisplatin-based chemotherapy // Ann. Oncol. 8: 41−47, 1997.
- Papadimitris C., Papadimitriou C.S., Kokolakis N., et al. Late relapse of non-seminomatous germ cell tumor of the testis: successful treatment with salvage chemotherapy alone // Urology. 1997. 49: 469−470.
- Rutherford E.E., Ferguson J.L., Geldart T.R., et al. Late relapse of metastatic non-seminomatous testicular germ cell tumors // Clinical Radiology. 2006. 61, 907−915.
- Fossa S., Bokemeyer C., Gerl A. et al. Treatment outcome of patients with brain metastases from malignant germ cell tumors // Cancer. 1999. Vol.85(4). P.988−997.
- Flechon A., Culine S., Theodore C., Droz J. Pattern of relapse after first line treatment of advanced stage germ cell tumors // J. Europ. Urology. 2005. Vol. 48. P. 957−964.2